-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
yesterday, Gilead Sciences and its Kite company, oNKo-innate, jointly announced that they had agreed to a three-year research collaboration on cancer immunotherapy to discover and develop the next generation of natural killer cells (NK) therapies.Current cancer immunotherapy methods focus on the anti-tumor immune response that activates T-cell-mediated. Like T cells, NK cells are a class of lymphocytes (white blood cells) that play an important role in the immune system. Both NK and T cells have the potential to attack cancer cells, but the mechanisms for killing tumor cells are different. Therefore, proper activation and targeting of NK cells may work in synergy with T-cell-mediated anti-tumor therapies.Under the terms of the agreement, oNKo-innate will receive an advance payment and will be eligible for additional payments based on potential clinical, regulatory and commercial milestones, as well as a share of future sales for this co-development therapy. oNKo-innate will use its genome-wide screening technology and its proprietary technology platform to help identify new immunotherapy targets that enhance the immune effectiveness of NK cells against tumors and to develop new NK cell therapies.“ Gilead Sciences is pleased to be working with oNKo-innate," said Dr. William Lee, Executive Vice President, Gilead Scientific Research. "
(Drug Mingkangde
)